Nextcure provides year-end clinical pipeline updates

Beltsville, md., dec. 14, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline.
NXTC Ratings Summary
NXTC Quant Ranking